Updates on Chemotherapy-Induced Nausea and Vomiting Management

Slideshow

This slideshow reviews the latest clinical updates surrounding the management of treatment-associated nausea and vomiting, including recommendations, newly approved agents, and more.

Nausea and vomiting are known unwanted side effects associated with cancer treatment, including chemotherapy. In some cases, chemotherapy-induced nausea and vomiting (CINV) can be debilitating for patients, and prevention is key. These slides provide insight into CINV management, recent drug approvals in this area, and current treatment recommendations.

Recent Videos
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
Related Content
The intravenous formulation of tocilizumab-anoh for CRS is expected to launch in the US on August 31, 2025.

FDA OKs Intravenous Tocilizumab Biosimilar in Cytokine Release Syndrome

Russ Conroy
August 6th 2025
Article

The intravenous formulation of tocilizumab-anoh for CRS is expected to launch in the US on August 31, 2025.

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 4th 2025
Podcast

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

FDA Accepts sBLA, Grants Priority Review to Liso-Cel in Pretreated MZL

FDA Accepts sBLA, Grants Priority Review to Liso-Cel in Pretreated MZL

Tim Cortese
August 5th 2025
Article

Results from the marginal zone lymphoma cohort of the TRANSCEND FL trial showed liso-cel elicited an ORR of 95.5% and a CR rate of 62.1%.

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
July 31st 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.

Data Show MRD in Nearly Half of Ovarian Cancer Population in Remission

Russ Conroy
August 4th 2025
Article

Further studying the biology of minimal residual disease may uncover ovarian cancer vulnerabilities and inform more effective therapies.

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Russ Conroy
August 4th 2025
Article

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.